A recent study indicates that individuals who discontinue popular weight-loss injections like Mounjaro or Wegovy can put back on lost weight far faster than those who stop conventional diet and exercise plans.
Research printed in a major health publication points out that while overweight people frequently drop about a fifth of their total mass while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals buying these drugs should be cognizant of the potential of quick weight regain when the medication ends," cautioned lead investigator Dr. Susan Jebb.
This pace of regain suggests a reversion to original weight in about a year and a half.
Weighing Therapies
The research, which looked at dozens of trials involving thousands of participants, contrasted the results of GLP-1 agonists with older methods.
Researchers emphasize that individuals who lose weight through dieting usually have a less rapid weight regain—perhaps 0.1 kg a month—post-intervention.
Explaining the Quick Rebound
Doctors propose the way of the drugs explains the heightened regain.
The injections imitate a body's own chemical called GLP-1, which helps regulate hunger.
"Artificially providing the hormone concentrations far above than the body's typical production might result in the body to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' means hunger is unsuppressed, making excessive eating a significant risk."
A Chronic Disease?
The NHS recommend the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
Many experts argue that, given the high risk of weight regain, the therapy is often ongoing.
This view is echoed by pharmaceutical companies, who say that the results "highlight the persistent nature of obesity," akin to managing diseases like diabetes.
User Experiences
Users who have discontinued the jabs describe a powerful resurgence of hunger.
"I experienced something flipping and I was suddenly extremely hungry," recalled a patient.
This difficulty is compounded if patients have not established lasting dietary or behavioural modifications during treatment.
Widespread Adoption
Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Use is more common among females compared to men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
Ultimately, experts caution that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone solution and maintained weight loss hinges on combined lifestyle changes.
